After signing up, you'll start to receive regular news updates from us.
Cardinal Health to Collaborate with Wyeth on Cell Line Development
Complete the form below to unlock access to ALL audio articles.
Cardinal Health has announced it has entered a feasibility agreement with Wyeth, acting through its Wyeth Pharmaceuticals division, to develop cell lines using Cardinal Health’s Gene Product Expression (GPEx®) cell line engineering technology.
Cardinal Health will use its patented GPEx® technology to engineer cell lines that express two undisclosed biopharmaceutical molecules in experiments that will determine if the GPEx® approach is a feasible augmentation to Wyeth’s current production methods.
"Wyeth has taken a leadership position among major pharmaceutical companies to seriously move into large molecule therapeutics and has a great track record with biopharmaceutical R&D, manufacturing and commercialization," said Paul Weiss, PhD, president of Cardinal Health’s biopharmaceutical development services center.
"We feel confident that the speed and high expression capabilities of our GPEx® technology will be attractive to Wyeth as they evaluate additional platforms to rapidly and cost-effectively produce biopharmaceuticals."
